mk-0616
merck
['cardio']
the experimental oral pcsk9 inhibitor mk-0616 was associated w/ a significant reduction in ldl-c in patients w/ hypercholesterolemia &amp; was well tolerated, according to a phase 2b, randomized international trial presented at #acc23/#wccardio. read more: 
Official American College of Cardiology account. Join us to transform cardiovascular care & improve heart health. Find us: @JACCJournals @Cardiology